Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
Journal: Dermatology and therapy
Published: August 04, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
Journal: The British journal of dermatology
Published: June 25, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.
Journal: The British journal of dermatology
Published: June 25, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
Journal: The British journal of dermatology
Published: June 13, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.
Journal: Dermatology and therapy
Published: April 09, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Journal: American journal of clinical dermatology
Published: April 07, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: January 10, 2025
A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa.
Journal: The Journal of investigative dermatology
Published: January 07, 2025
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Journal: Journal of the American Academy of Dermatology
Published: December 13, 2024
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.
Journal: Journal of the American Academy of Dermatology
Published: December 06, 2024
Last Updated: 09/26/2026